FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2461949293> ?p ?o ?g. }

• W2461949293 endingPage "21" @default.
• W2461949293 startingPage "815" @default.
• W2461949293 abstract "The experience acquired and a better understanding of the pathogenesis of cerebral impairment in elderly subjects have enabled the authors to propose certain rules for therapeutic trials in such patients. The patient population should be homogeneous with regard to the severity of cerebral impairment. A clear-cut distinction should be made between at least two categories of patients: those at home and those in institutions. Impairments due to different causes (arteriopathy, parkinsonism, traumas, chronic intoxication, idiopathic) require different trials. Criteria of assessment should intervene at recruitment to homogenize the degrees of severity. They should be consistent with the purpose of the trial (pragmatic or explicative) and with its duration and the number of subjects involved. In pragmatic trials assessment should be based on changes in social and affective relationships or even changes in the likelihood of admission to an institution. Assessment scales using psychometric, clinical and socio-affective criteria may be used provided the importance of each criterion is weighed beforehand and the results concern overall changes rather than changes of any particular item. Such trials are necessarily protracted and involve a large number of patients. Psychometric and neurophysiological tests seem to be best suited to explicative trials, as they are reproducible and easily performed. While they may demonstrate the effects of the drug on memory, mood, alertness, etc., or merely show an impact on the central nervous system, this does not necessarily mean that they are of interest in senile cerebral impairment. Explicative trials, which are shorter and require less patients, help to select the drugs suitable for long-term trials. Finally concerning the three topics constantly debated when organizing such trials, viz, maximum age of the subjects, use of a cross-over method and association of psychotropic drugs, the authors' opinion is: (a) there is no reason for an upper age limit; (b) cross-over studies should be avoided, and (c) psychotropic drugs must be banned in short-term trials but are unavoidable in long-term trials." @default.
• W2461949293 created "2016-07-22" @default.
• W2461949293 creator A5036650766 @default.
• W2461949293 creator A5036988353 @default.
• W2461949293 date "1983-03-24" @default.
• W2461949293 modified "2023-09-23" @default.
• W2461949293 title "[Viewpoints on the therapeutic trials in senile cerebral insufficiency]." @default.
• W2461949293 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6220329" @default.
• W2461949293 hasPublicationYear "1983" @default.
• W2461949293 type Work @default.
• W2461949293 sameAs 2461949293 @default.
• W2461949293 citedByCount "0" @default.
• W2461949293 crossrefType "journal-article" @default.
• W2461949293 hasAuthorship W2461949293A5036650766 @default.
• W2461949293 hasAuthorship W2461949293A5036988353 @default.
• W2461949293 hasConcept C118552586 @default.
• W2461949293 hasConcept C126322002 @default.
• W2461949293 hasConcept C200678441 @default.
• W2461949293 hasConcept C2776525014 @default.
• W2461949293 hasConcept C2779134260 @default.
• W2461949293 hasConcept C2780733359 @default.
• W2461949293 hasConcept C2908647359 @default.
• W2461949293 hasConcept C2992672634 @default.
• W2461949293 hasConcept C535046627 @default.
• W2461949293 hasConcept C70410870 @default.
• W2461949293 hasConcept C71924100 @default.
• W2461949293 hasConcept C99454951 @default.
• W2461949293 hasConceptScore W2461949293C118552586 @default.
• W2461949293 hasConceptScore W2461949293C126322002 @default.
• W2461949293 hasConceptScore W2461949293C200678441 @default.
• W2461949293 hasConceptScore W2461949293C2776525014 @default.
• W2461949293 hasConceptScore W2461949293C2779134260 @default.
• W2461949293 hasConceptScore W2461949293C2780733359 @default.
• W2461949293 hasConceptScore W2461949293C2908647359 @default.
• W2461949293 hasConceptScore W2461949293C2992672634 @default.
• W2461949293 hasConceptScore W2461949293C535046627 @default.
• W2461949293 hasConceptScore W2461949293C70410870 @default.
• W2461949293 hasConceptScore W2461949293C71924100 @default.
• W2461949293 hasConceptScore W2461949293C99454951 @default.
• W2461949293 hasIssue "13" @default.
• W2461949293 hasLocation W24619492931 @default.
• W2461949293 hasOpenAccess W2461949293 @default.
• W2461949293 hasPrimaryLocation W24619492931 @default.
• W2461949293 hasRelatedWork W1995185349 @default.
• W2461949293 hasRelatedWork W1995338381 @default.
• W2461949293 hasRelatedWork W1998192739 @default.
• W2461949293 hasRelatedWork W2005971986 @default.
• W2461949293 hasRelatedWork W2047498965 @default.
• W2461949293 hasRelatedWork W2056500109 @default.
• W2461949293 hasRelatedWork W2071907783 @default.
• W2461949293 hasRelatedWork W2146075133 @default.
• W2461949293 hasRelatedWork W2326350344 @default.
• W2461949293 hasRelatedWork W2461949293 @default.
• W2461949293 hasVolume "12" @default.
• W2461949293 isParatext "false" @default.
• W2461949293 isRetracted "false" @default.
• W2461949293 magId "2461949293" @default.
• W2461949293 workType "article" @default.